425 related articles for article (PubMed ID: 33752265)
1. Emerging glyco-based strategies to steer immune responses.
Anderluh M; Berti F; Bzducha-Wróbel A; Chiodo F; Colombo C; Compostella F; Durlik K; Ferhati X; Holmdahl R; Jovanovic D; Kaca W; Lay L; Marinovic-Cincovic M; Marradi M; Ozil M; Polito L; Reina-Martin JJ; Reis CA; Sackstein R; Silipo A; Švajger U; Vaněk O; Yamamoto F; Richichi B; van Vliet SJ
FEBS J; 2021 Aug; 288(16):4746-4772. PubMed ID: 33752265
[TBL] [Abstract][Full Text] [Related]
2. Impact of glycans on T-cell tolerance to glycosylated self-antigens.
Purcell AW; van Driel IR; Gleeson PA
Immunol Cell Biol; 2008 Oct; 86(7):574-9. PubMed ID: 18626489
[TBL] [Abstract][Full Text] [Related]
3. CAR-Ts: new perspectives in cancer therapy.
Abrantes R; Duarte HO; Gomes C; Wälchli S; Reis CA
FEBS Lett; 2022 Feb; 596(4):403-416. PubMed ID: 34978080
[TBL] [Abstract][Full Text] [Related]
4. Glycan-Based Cell Targeting To Modulate Immune Responses.
Johannssen T; Lepenies B
Trends Biotechnol; 2017 Apr; 35(4):334-346. PubMed ID: 28277249
[TBL] [Abstract][Full Text] [Related]
5. Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer.
Rabinovich GA; Croci DO
Immunity; 2012 Mar; 36(3):322-35. PubMed ID: 22444630
[TBL] [Abstract][Full Text] [Related]
6. Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: a critical review.
Maverakis E; Kim K; Shimoda M; Gershwin ME; Patel F; Wilken R; Raychaudhuri S; Ruhaak LR; Lebrilla CB
J Autoimmun; 2015 Feb; 57():1-13. PubMed ID: 25578468
[TBL] [Abstract][Full Text] [Related]
7. Canvassing Prospects of Glyco-Nanovaccines for Developing Cross-Presentation Mediated Anti-Tumor Immunotherapy.
Makandar AI; Jain M; Yuba E; Sethi G; Gupta RK
Vaccines (Basel); 2022 Nov; 10(12):. PubMed ID: 36560459
[TBL] [Abstract][Full Text] [Related]
8. Immune regulatory networks coordinated by glycans and glycan-binding proteins in autoimmunity and infection.
Pinho SS; Alves I; Gaifem J; Rabinovich GA
Cell Mol Immunol; 2023 Oct; 20(10):1101-1113. PubMed ID: 37582971
[TBL] [Abstract][Full Text] [Related]
9. Glycans as Key Checkpoints of T Cell Activity and Function.
Pereira MS; Alves I; Vicente M; Campar A; Silva MC; Padrão NA; Pinto V; Fernandes Â; Dias AM; Pinho SS
Front Immunol; 2018; 9():2754. PubMed ID: 30538706
[TBL] [Abstract][Full Text] [Related]
10. Plant lectins and their usage in preparing targeted nanovaccines for cancer immunotherapy.
Gupta B; Sadaria D; Warrier VU; Kirtonia A; Kant R; Awasthi A; Baligar P; Pal JK; Yuba E; Sethi G; Garg M; Gupta RK
Semin Cancer Biol; 2022 May; 80():87-106. PubMed ID: 32068087
[TBL] [Abstract][Full Text] [Related]
11. Regulating the regulators: Is introduction of an antigen-specific approach in regulatory T cells the next step to treat autoimmunity?
Janssens I; Cools N
Cell Immunol; 2020 Dec; 358():104236. PubMed ID: 33137651
[TBL] [Abstract][Full Text] [Related]
12. Various Tastes of Sugar: The Potential of Glycosylation in Targeting and Modulating Human Immunity via C-Type Lectin Receptors.
Busold S; Nagy NA; Tas SW; van Ree R; de Jong EC; Geijtenbeek TBH
Front Immunol; 2020; 11():134. PubMed ID: 32117281
[TBL] [Abstract][Full Text] [Related]
13. Aiming for the Sweet Spot: Glyco-Immune Checkpoints and γδ T Cells in Targeted Immunotherapy.
Bartish M; Del Rincón SV; Rudd CE; Saragovi HU
Front Immunol; 2020; 11():564499. PubMed ID: 33133075
[TBL] [Abstract][Full Text] [Related]
14. Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation.
van Kooyk Y; Unger WW; Fehres CM; Kalay H; García-Vallejo JJ
Mol Immunol; 2013 Sep; 55(2):143-5. PubMed ID: 23158834
[TBL] [Abstract][Full Text] [Related]
15. The tumour glyco-code as a novel immune checkpoint for immunotherapy.
RodrÍguez E; Schetters STT; van Kooyk Y
Nat Rev Immunol; 2018 Mar; 18(3):204-211. PubMed ID: 29398707
[TBL] [Abstract][Full Text] [Related]
16. GLYCO: a tool to quantify glycan shielding of glycosylated proteins.
Lee M; Reveiz M; Rawi R; Kwong PD; Chuang GY
Bioinformatics; 2022 Jan; 38(4):1152-1154. PubMed ID: 34864901
[TBL] [Abstract][Full Text] [Related]
17. Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens.
Fehres CM; Kalay H; Bruijns SC; Musaafir SA; Ambrosini M; van Bloois L; van Vliet SJ; Storm G; Garcia-Vallejo JJ; van Kooyk Y
J Control Release; 2015 Apr; 203():67-76. PubMed ID: 25656175
[TBL] [Abstract][Full Text] [Related]
18. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
[TBL] [Abstract][Full Text] [Related]
19. The melanoma tumor glyco-code impacts human dendritic cells' functionality and dictates clinical outcomes.
Sosa Cuevas E; Roubinet B; Mouret S; Thépaut M; de Fraipont F; Charles J; Fieschi F; Landemarre L; Chaperot L; Aspord C
Front Immunol; 2023; 14():1120434. PubMed ID: 36891308
[TBL] [Abstract][Full Text] [Related]
20. Coupling pathogen recognition to innate immunity through glycan-dependent mechanisms.
Davicino RC; Eliçabe RJ; Di Genaro MS; Rabinovich GA
Int Immunopharmacol; 2011 Oct; 11(10):1457-63. PubMed ID: 21600310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
